D
D. R. Ferry
Researcher at University of Birmingham
Publications - 48
Citations - 6299
D. R. Ferry is an academic researcher from University of Birmingham. The author has contributed to research in topics: Voltage-dependent calcium channel & Ifosfamide. The author has an hindex of 32, co-authored 48 publications receiving 5976 citations. Previous affiliations of D. R. Ferry include New Cross Hospital & Eli Lilly and Company.
Papers
More filters
Journal Article
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
D. R. Ferry,A Smith,J Malkhandi,D. Fyfe,P G deTakats,David E. Anderson,J Baker,David J. Kerr +7 more
TL;DR: In conclusion, quercetin can be safely administered by i.v. bolus at a dose injection and evidence of antitumor activity was seen.
Journal ArticleDOI
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Matthew T. Seymour,Tim Maughan,Jonathan A. Ledermann,C. Topham,Roger D James,Stephen J. Gwyther,David Smith,Stephen F Shepherd,Anthony Maraveyas,D. R. Ferry,A Meade,L.C. Thompson,Gareth Griffiths,Mahesh K. B. Parmar,Richard Stephens +14 more
TL;DR: The data challenge the assumption that, in this non-curative setting, maximum tolerable treatment must necessarily be used first-line in patients with advanced colorectal cancer, and suggest the staged approach of initial single-agent treatment upgraded to combination when required is not worse than first- line combination.
Journal ArticleDOI
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
Michael Cullen,Lucinda Billingham,C.M. Woodroffe,A. D. Chetiyawardana,N.H. Gower,R. Joshi,D. R. Ferry,Robin M. Rudd,Stephen G. Spiro,J. E. Cook,C. Trask,E. Bessell,C. K. Connolly,Jeffrey S Tobias,Robert L. Souhami +14 more
TL;DR: In this paper, the authors describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.
Journal ArticleDOI
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Leonard W. Seymour,D. R. Ferry,David E. Anderson,Stuart Hesslewood,Peter J. Julyan,Richard Poyner,J. Doran,Annie M. Young,Sally Burtles,David J. Kerr +9 more
TL;DR: Liver-specific doxorubicin delivery is achievable using galactosamine-modified polymers, and targeting is also seen in primary hepatocellular tumors, and the recommended PK2 dose is 120 mg/m(2), administered every 3 weeks by IV infusion.
Journal ArticleDOI
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
Atsushi Ohtsu,Jaffer A. Ajani,Yu Xian Bai,Yung-Jue Bang,Hyun Cheol Chung,Hong Ming Pan,Tarek Sahmoud,Lin Shen,Kun-Huei Yeh,Keisho Chin,Kei Muro,Yeul Hong Kim,D. R. Ferry,Niall C. Tebbutt,Salah-Eddin Al-Batran,Heind Smith,Chiara Costantini,Syed Rizvi,David Lebwohl,Eric Van Cutsem +19 more
TL;DR: Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy and the safety profile observed for Everolimus was consistent with that observed forEverolimus in other cancers.